China’s pharmaceutical industry is rapidly evolving, with Jiangsu Hengrui Pharmaceuticals surpassing AstraZeneca as the top global clinical trial sponsor. Driven by regulatory reforms and cost-effective trial management, China is establishing itself as a key R&D hub. Significant collaborations, such as Hengrui’s partnership with Merck & Co. and a $12 billion deal with GSK, highlight this shift.
The latest Citeline report shows oncology remains the leading area for clinical trials, despite a slowdown in growth. Central nervous system (CNS) disorders and autoimmune diseases are also gaining attention, with a notable increase in trials for pain, depression, and innovative therapies. Cardiovascular research is rapidly expanding, fueled by demographic factors and advancements in treatment modalities. Overall, digital health technologies and AI are expected to further accelerate drug development in the industry.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.pharmavoice.com/news/chinese-china-drug-clinical-trial-pharma-jiangsu-hengrui/804665/
